Independent analysis puts a WXT exenatide lot at 97.4%, against 93.5% on the certificate
The supplier confirmed the determination and supplied the method behind its own figure inside a week.
The archive — 2025
Page 62 of 68 of this archive, newest first.
The steps get smaller as the ladder gets higher, and that is deliberate
What the published pharmacokinetics permit, what the labels state, and where the two diverge.
What happens in solution that does not happen in the cake
Every degradation pathway accelerates by orders of magnitude on reconstitution, because the solvent that lyophilisation removed is the reagent most of them need.
SGN names the synthesis and fill sites behind its catalogue
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
A shortage listing ends. 13 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
Halvard & Pike Apothecary of Portland, Maine enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
Six words a verification badge would need to mean anything
What a verification mark would have to carry to be checkable: a date, a lot, a method, a submitter and a link to the report.
The dose you were told to reach and the dose you will actually stay on
The published ladder exists because a protocol needed a single number. Practice has never followed it exactly, and the regulatory file never assumed it would.
What the new Norway guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
STEP 5 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The United Arab Emirates declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Denmark health authority warns on falsified tirzepatide pens
Reported from the analysis, not from a warning notice.
What TRIUMPH-3 tells us about maintenance, and what it does not
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
Five lines that would change what a certificate is worth
A reader holding a certificate can work out what it does not cover in about ninety seconds, and that is a useful ninety seconds.
A supplier suspends shipping to Portugal after 23 consecutive customs detentions
The route did not close because of a rule about peptides.
What changed at BCH in February, and what the company says prompted it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Janoshik result on a Suzhou mazdutide lot lands 4.0 points above the supplier’s stated figure
The supplier confirmed the determination and supplied the method behind its own figure inside a week.
From the floor in Wuxi: 5 posters, one theme
Reported from the sessions, and from the two hours afterwards.
The glucagon receptor arm, and why it is the hardest to reason about
What adding GIP activity does, on the current evidence, and what remains unresolved.
Why a dead-clean sterile filter can pass pyrogen straight through
The limit for a parenteral product is calculable from the dose and the body weight in two lines. Almost nobody in this trade performs the calculation.
Attribution is the hard part
Pancreatitis is rare, was adjudicated in the outcome programmes, and did not show the imbalance early case reports suggested.
JEEP names the synthesis and fill sites behind its catalogue
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
SURMOUNT-4 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Independent analysis puts a GGPeps tirzepatide lot at 96.6%, against 93.7% on the certificate
The result is unremarkable. What the report states alongside it is not.
The relabeller trading as Vantris Bio enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
Who signed this, and what did they undertake by signing it
What the Journal asks when a document arrives unsigned, and what the answers have been.
The advice is mostly reasonable. The certainty is not earned.
The gap between a defensible recommendation and a confident one is where most of the harm in this subject lives.
What a 31% rise in coupling-reagent prices does to a 20 mg vial
Follow the resin, not the catalogue.
What the new Brazil guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.